Navigation Links
Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy
Date:12/7/2013

ve limited options. And while most adults with ALL respond to drug treatment, as many as half ultimately relapse, putting the overall cure rate for the disease among adults at only around 40 percent. New therapies for both these groups of high-risk patients are acutely needed.

"Our results serve as another important milestone in demonstrating the potential of this treatment for patients who have no other therapeutic options," said study author Stephan A. Grupp, MD, PhD, of the Children's Hospital of Philadelphia and a professor of Pediatrics at the Perelman School of Medicine. "These data also demonstrate that these engineered 'hunter' cells greatly expand and then persist in patients, allowing for long-term disease control. We are looking forward to testing these cells in upcoming multicenter pediatric and adult trials."

During the pilot study for CLL, patients received a wide range of cell doses, but the Penn team saw no relationship between the number of cells infused and the responses or toxicities associated with the therapy. To refine the treatment approach, the Penn team launched a randomized Phase II study comparing two different doses, each of which is given as a single outpatient infusion. So far, however, the team has again seen no difference in which amount of cells is more effective or associated with greater toxicities.

Tests Pinpoint Cause, Management Technique for Side Effects

In the trials for both CLL and ALL, all responding patients experienced a cytokine release syndrome that the researchers now know marks the process of the engineered cells multiplying and attacking tumor cells in the body. During this time, patients typically experience varying degrees of flu-like symptoms, with high fevers, nausea, muscle pain, and in some cases, low blood pressure and breathing difficulties. The team has learned this reaction can be managed, if necessary, using tocilizumab, an immunosuppressant drug which tamps down
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. Singapore joins global translational medicine network as Asia-Pacific hub
2. Penn Dental Medicine team identifies molecule critical to healing wounds
3. Sons of cocaine-using fathers may resist addiction to drug, Penn Medicine study suggests
4. Osteoarthritis medicine delivered on-demand
5. College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases
6. Ludwig scientist Richard D. Kolodner elected to the Institute of Medicine
7. Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicines 2013 Lienhard Award
8. Institute of Medicine Elects 70 New Members, 10 Foreign Associates
9. Carnegie Mellon President Subra Suresh elected to Institute of Medicine
10. Institute of Medicine honors members for outstanding service
11. Wyss Institute core faculty member elected to the Institute of Medicine of the National Academies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn Medicine team reports on study of first 59 leukemia patients who received cell therapy
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... biotechnological company, has presented at the CIC ... (Derio), the first DNA chip concerning diagnosis ... the discrimination between normal, steatosis and NASH ... a progressive disease of the liver of ...
... system is a marvel of versatility, creating a variety of ... To carry out these tasks, immune cells follow a career ... a report in the May 2005 issue of Immunity, Fox ... Ph.D. and Dietmar J. Kappes, Ph.D., show that cell-receptor signaling ...
... of the National Institutes of Health, have built the ... Scientists searching for genes that go awry and cause ... point of reference because it pinpoints which genes are ... normal conditions, without known disease. , Scientists can compare ...
Cached Biology News:Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3Gov't Creates Gene Database of Normal Human Tissues 2Gov't Creates Gene Database of Normal Human Tissues 3Gov't Creates Gene Database of Normal Human Tissues 4
(Date:12/24/2014)... Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading ... reproductive medicine. In his new role as treasurer, ... board and will have a voice in furthering the ... supported ASRM since 1984 when he joined while conducting ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2
... Laboratories, pathologist, Ronald L. Weiss, MD, MBA, FCAP, received ... Pathologists at CAP ,11, the organization,s annual meeting, held ... the award honors members "who have made a broad ... of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ) ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... announced financial results for the third quarter of 2011. For ... net loss of $4.6 million, or $0.10 per share, as ... per share, for the third quarter of 2010. As of ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5